1. Home
  2. PCRX vs BFS Comparison

PCRX vs BFS Comparison

Compare PCRX & BFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.77

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

BFS

Saul Centers Inc.

HOLD

Current Price

$33.25

Market Cap

809.1M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
BFS
Founded
2006
1993
Country
United States
United States
Employees
N/A
98
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
809.1M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
BFS
Price
$22.77
$33.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$30.25
$44.00
AVG Volume (30 Days)
515.7K
40.3K
Earning Date
04-30-2026
05-11-2026
Dividend Yield
N/A
6.92%
EPS Growth
107.44
N/A
EPS
0.07
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$6.78
$0.30
Revenue Next Year
$8.54
$5.67
P/E Ratio
$336.79
$30.48
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$29.16
52 Week High
$27.64
$35.45

Technical Indicators

Market Signals
Indicator
PCRX
BFS
Relative Strength Index (RSI) 41.55 39.62
Support Level $22.13 $33.14
Resistance Level $24.20 $34.99
Average True Range (ATR) 1.26 0.79
MACD -0.25 -0.15
Stochastic Oscillator 8.81 18.64

Price Performance

Historical Comparison
PCRX
BFS

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

Share on Social Networks: